Journal article
Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients
Abstract
BackgroundImmune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the therapeutic benefit and allow studying new approaches for resistant patients.MethodsWe analyzed the TCGA cohort of HNSCC patients in relation to their activation of 26 immune gene expression signatures, as well as their cell …
Authors
Sacconi A; Muti P; Pulito C; Urbani G; Allegretti M; Pellini R; Mehterov N; Ben-David U; Strano S; Bossi P
Journal
Molecular Cancer, Vol. 22, No. 1,
Publisher
Springer Nature
DOI
10.1186/s12943-023-01905-9
ISSN
1476-4598